CORMEDIX INC. ANNOUNCES THE APPOINTMENT OF CHIEF EXECUTIVE OFFICER Joseph Todisco to join CorMedix as Chief Executive Officer; Brings significant experience in commercial strategy, business operations and leadership, and

INC. ANNOUNCES THE APPOINTMENT OF CHIEF EXECUTIVE OFFICER

Joseph Todisco to join CorMedix as Chief Executive

Officer; Brings significant experience in commercial strategy, business operations and leadership, and specialty pharmaceuticals industry

NJ - March 17, 2022 - CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing

therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced the appointment of Joseph

Todisco as Chief Executive Officer of the company. Mr. Todisco also will join the CorMedix Board of Directors. The company expects Mr.

Todisco to join CorMedix on May 16th or such earlier date as he completes his contractual responsibilities to his current employer.

Myron Kaplan, Chairman

of CorMedix's Board of Directors commented, "We are delighted to welcome Joe to CorMedix as the new Chief Executive Officer.

Having built pharmaceutical businesses in the past and led successful commercial organizations globally, Joe brings significant and relevant

experience to the company. The Board believes he is the right person to lead CorMedix as we continue to advance DefenCath and aim to build

a successful commercial franchise around our lead product. The Board also is grateful for Dr. Matt David's leadership throughout

the interim period and we look forward to continuing to work with him and the executive team."

strong late-stage pre-commercial asset in DefenCath with a compelling value proposition for patients in the hemodialysis community,"

said Mr. Todisco. "I am excited to be taking on this role, and I look forward to working alongside the CorMedix board, management,

and employees to continue building the company as we prepare for a potential commercial launch in hemodialysis and explore new opportunities

announcement of our resubmission of the DefenCath NDA to the FDA, the CorMedix team has been active on all fronts as we have worked through

manufacturing challenges and continued to build our understanding of the commercial opportunity for DefenCath," said Dr. Matt David,

interim CEO and Chief Financial Officer. "I join my colleagues in welcoming Joe to CorMedix as Chief Executive Officer. I look forward

to working closely with Joe as we seek to transform CorMedix to a commercial stage entity."

Joe Todisco is an experienced

pharmaceutical industry leader with a track record of building businesses globally and providing commercial leadership over the last 20

years. Previously, Mr. Todisco was a senior executive at Amneal Pharmaceuticals, where for the past 11 years he has held various roles,

most recently as Executive Vice President, Chief Commercial Officer where he was responsible for Amneal Specialty, a growing branded products

business with $380 million in revenue and approximately 200 employees. During his tenure at Amneal, Mr. Todisco held roles overseeing

corporate development and international operations, leading commercial teams in several international markets including the UK, Australia

and Germany, as well as leading Amneal's merger integration with Impax Laboratories in 2018.

Mr. Todisco was previously

Co-Founder and managing executive of Gemini Laboratories, a specialty pharmaceutical company focused on the sales and marketing for niche

branded products in the US Market. Gemini Laboratories was established as an affiliate of Amneal Pharmaceuticals and was subsequently

acquired by Amneal in 2018.

Prior to joining Amneal,

Mr. Todisco was Vice President, Business Development & Licensing at Ranbaxy, Inc. where he was responsible for developing and executing

Ranbaxy's North American commercial business strategy. Prior to Ranbaxy, he held various roles at Par Pharmaceutical, and in his

earlier career held positions at Oppenheimer & Company and Marsh & McLennan Companies. Mr. Todisco obtained his MBA in finance

from Fordham Graduate School of Business and his BA in Economics from Georgetown University.

CorMedix Inc. is a biopharmaceutical

company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory

diseases. The company is focused on developing its lead product DefenCath , a novel, antibacterial and antifungal solution designed

to prevent costly and life-threatening bloodstream infections associated with the use of central venous catheters in patients undergoing

chronic hemodialysis. DefenCath has been designated by FDA as Fast Track and as a Qualified Infectious Disease Product (QIDP), and the

original New Drug Application (NDA) received priority review in recognition of its potential to address an unmet medical need. QIDP provides

for an additional five years of marketing exclusivity, which will be added to the five years granted to a New Chemical Entity upon approval

of the NDA. CorMedix also committed to conducting a clinical study in pediatric patients using a central venous catheter for hemodialysis

when the NDA is approved, which will add an additional six months of marketing exclusivity when the study is completed. The company received

a Complete Response Letter from FDA stating that the NDA could not be approved until satisfactory resolution of deficiencies at the contract

manufacturing facility, including in-process controls for the filling operation. The deficiencies have been addressed in the resubmitted

NDA which is being reviewed by FDA for acceptance for filing. CorMedix also intends to develop DefenCath as a catheter lock solution for

use in other patient populations. It is leveraging its taurolidine technology to develop a pipeline of antimicrobial medical devices,

with programs in surgical sutures and meshes, and topical hydrogels. The Company is also working with top-tier researchers to develop

taurolidine-based therapies for rare pediatric cancers. Neutrolin is CE Marked and marketed in Europe and other territories as a

medical device. For more information, visit: www.cormedix.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning

of the Private Securities Litigation Reform Act of 1995 that are subject to risks and uncertainties. All statements, other than statements

of historical facts, regarding management's expectations, beliefs, goals, plans or CorMedix's prospects, future financial

position, financing plans, future revenues and projected costs should be considered forward-looking. Readers are cautioned that actual

results may differ materially from projections or estimates due to a variety of important factors, including: the results of our discussions

with the FDA regarding the DefenCath development path for marketing authorization; the resources needed to secure approval of the new

drug application for DefenCath from the FDA; our ability to address the deficiencies identified at our CMO in connection with the manufacture

of DefenCath; the risks and uncertainties associated with CorMedix's ability to manage its limited cash resources and the impact

on current, planned or future research, including the continued development of DefenCath/Neutrolin and research for additional uses for

taurolidine; obtaining additional financing to support CorMedix's research and development and clinical activities and operations;

preclinical results are not indicative of success in clinical trials and might not be replicated in any subsequent studies or trials;

and the ability to retain and hire necessary personnel to staff our operations appropriately. We continue to assess to what extent the

uncertainty surrounding the Coronavirus pandemic may impact our business and operations. These and other risks are described in greater

detail in CorMedix's filings with the SEC, copies of which are available free of charge at the SEC's website at www.sec.gov

or upon request from CorMedix. CorMedix may not actually achieve the goals or plans described in its forward-looking statements, and investors

should not place undue reliance on these statements. CorMedix assumes no obligation and does not intend to update these forward-looking

statements, except as required by law.